依西酞普兰
文拉法辛
西酞普兰
医学
舍曲林
抗抑郁药
氟西汀
度洛西汀
内科学
帕罗西汀
米氮平
药理学
麻醉
血清素
受体
病理
替代医学
海马体
作者
Marika Alborghetti,Luana Lionetto,Ginevra Lombardozzi,Luca Montaguti,Giada Trovini,D. Donato,Giuseppe Costanzi,Donatella De Bernardini,Federica Catapano,Michele Surano,Ilaria Pagano,Alessia Ceccherelli,Edoardo Bianchini,Giorgio Di Lorenzo,Maurizio Simmaco,Giovanni Martinotti,Georgios D. Kotzalidis,Ferdinando Nicoletti,Sergio De Filippis
标识
DOI:10.2174/011570159x356952241216172603
摘要
Introduction/Objective: Esketamine is administered intranasally in combination with at least another antidepressant in patients with treatment-resistant depression. Some of these antidepressants might affect ketamine’s pharmacokinetic profile by inhibiting cytochrome-P450 (CYP450) isoforms. Our aim was to establish how different types of combined antidepressants affect serum and salivary levels of esketamine at the time of maximum plasma concentrations and afterward in TRD patients receiving esketamine in a real-world context. Methods: Serum and salivary samples were collected from 53 patients receiving intranasal esketamine (56 mg) at baseline, after 20 min (roughly corresponding to Tmax), 7 hours (corresponding to the t½ value), 24, and 72 hours. Patients were stratified according to the combined antidepressant medication. Results: Salivary esketamine levels were several-fold higher than the corresponding serum levels at all time points, and showed high inter-individual variability. Serum 20-min post-esketamine levels and AUC0-72 levels were significantly higher in patients on antidepressants known to inhibit different isoforms of CYP450 (paroxetine, fluoxetine, duloxetine, venlafaxine), with respect to levels detected in patients on sertraline, citalopram, escitalopram, vortioxetine. These changes in the pharmacokinetic profile of esketamine did not affect the clinical outcome of esketamine. However, changes in systolic blood pressure in response to esketamine positively correlated with serum esketamine levels, suggesting a reduction of esketamine dose in patients with cardiovascular comorbidity under treatment with paroxetine, fluoxetine, duloxetine, venlafaxine. Conclusion: The CYP450-related status of co-administered antidepressants may affect esketamine levels. However, the small sample sizes of the co-administered drug subgroups and multiple prescriptions do not allow for drawing strong conclusions.
科研通智能强力驱动
Strongly Powered by AbleSci AI